Copenhagen, Denmark; 26 July 2002 - Genmab A/S (CSE: GEN and Neuer Markt: GE9D) announced that it will today submit an application to Deutsche Börse AG to de-list its Co Ownership Interests (COIS) from the Regulated Market of the Frankfurt Stock Exchange and for trading to be ended on the Neuer Markt.

On the approval of the application from Deutsche Börse trading in COIS will be stopped on the Neuer Markt and traded on the Regulated Market until delisting comes into effect. Upon final delisting from the Frankfurt Stock Exchange, all COISs will be dissolved and COIS shareholders will be credited with ordinary shares at the cost of Genmab. A public buy back offer to COIS holders is not planned.

Genmab's shares will continue to be listed on the Copenhagen Stock Exchange.

Since Genmab's IPO in October 2000 more than 95 percent of trading in the company's stock has taken place on the Copenhagen Stock Exchange. Genmab will continue to serve current and potential investors in Germany by maintaining investor and media relations and activities.

"After a great deal of consideration and consultation we have decided that delisting from the Neuer Markt is in the best interests of our shareholders and the company. By eliminating the duplication in financial reporting that comes with a double listing, Genmab will gain cost savings," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We highly value our German investors and will continue to work closely with the financial community in Germany."

Genmab will give further information including the specific dates for the transferal to the Regulated Market and when the delisting will come into effect, following the decision of Deutsche Börse on the delisting.